Protalix BioTherapeutics, Inc. has completed a private stock placement
March 2020 — Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Our role in the transaction
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
Boeser Frischfleisch has secured financing for the acquisition of Vion Crailsheim
Boeser Frischfleisch GmbH has secured financing in connection with the acquisition of the Crailsheim site from Vion Group. The site specializes in the slaughtering and cutting of cattle and pigs and plays an important role in the southern German meat industry. Through the acquisition, Boeser Frischfleisch expands its value chain and strengthens its position in a market characterized by ongoing structural change and consolidation.
Learn moreBolster Investment Partners has secured debt financing for the acquisition of Royal Taste Company
Bolster Investment Partners has partnered with Royal Taste Company, a leading Dutch custom signature coffee platform offering end-to-end sourcing, blending, roasting, packaging and delivery services. The partnership marks an important next step in Royal Taste Company’s growth trajectory, focused on further geographical expansion, commercial development and selective strategic acquisitions.
Learn moreIndigo Capital has acquired a minority stake in Vivason
Indigo Capital has acquired a minority stake in Vivason, a leading network of hearing care centers, to support the company’s growth and enable management to increase its ownership stake.
Learn more